Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $55.9 million.

  • Coherus Oncology's Operating Expenses rose 566.27% to $55.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.4 million, marking a year-over-year increase of 1110.71%. This contributed to the annual value of $378.6 million for FY2024, which is 1776.9% down from last year.
  • As of Q3 2025, Coherus Oncology's Operating Expenses stood at $55.9 million, which was up 566.27% from $55.7 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Operating Expenses registered a high of $250.4 million during Q1 2021, and its lowest value of $49.9 million during Q2 2024.
  • For the 5-year period, Coherus Oncology's Operating Expenses averaged around $108.5 million, with its median value being $104.2 million (2022).
  • Per our database at Business Quant, Coherus Oncology's Operating Expenses surged by 23247.56% in 2021 and then plummeted by 5035.56% in 2024.
  • Over the past 5 years, Coherus Oncology's Operating Expenses (Quarter) stood at $112.9 million in 2021, then decreased by 14.23% to $96.8 million in 2022, then skyrocketed by 65.66% to $160.4 million in 2023, then rose by 28.22% to $205.7 million in 2024, then crashed by 72.82% to $55.9 million in 2025.
  • Its Operating Expenses stands at $55.9 million for Q3 2025, versus $55.7 million for Q2 2025 and $53.0 million for Q1 2025.